DPYD Tip Sheet
The following information is intended for use by providers who are attempting to prescribe fluoropyrimidines, including fluorouracil (5-FU) and capecitabine to Biobank participants with certain DPYD genetic variants.
If you have questions, please call the pharmacogenomics consult pager at (303) 266-4510.
References:
Top Table:
- Adapted from the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing 2017 Update: Amstutz U et al. Clin Pharmacol Ther 2018; 103(2):210-16, PMID: 29152729, and November 2018 update at: https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/.
Bottom Table:
- EFUDEX Product Label. Rev 10/2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/016831Orig1s063lbl.pdf
- Carac Product Label. Rev 05/2021. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6795f2b1-1381-4a4f-ad34-2c28ebd1cfaf&type=display
- Dutch Pharmacogenetics Working Group. Fluorouracil cutaan 6192. Revised 05/13/2019. https://www.knmp.nl/media/1058
- Johnson MR et al. Clin Cancer Res 1999; 5(8):2006-11. PMID 10473079